A
Alejandro Forner
Researcher at University of Barcelona
Publications - 157
Citations - 22167
Alejandro Forner is an academic researcher from University of Barcelona. The author has contributed to research in topics: Hepatocellular carcinoma & Sorafenib. The author has an hindex of 34, co-authored 137 publications receiving 17528 citations. Previous affiliations of Alejandro Forner include Kindai University & Carlos III Health Institute.
Papers
More filters
Journal ArticleDOI
Sorafenib in Advanced Hepatocellular Carcinoma
Josep M. Llovet,Sergio Ricci,Vincenzo Mazzaferro,Philip Hilgard,Edward Gane,Jean-Frédéric Blanc,André Cosme de Oliveira,Armando Santoro,Jean-Luc Raoul,Alejandro Forner,Myron Schwartz,Camillo Porta,Stefan Zeuzem,Luigi Bolondi,Tim F. Greten,Peter R. Galle,Jean Francois Seitz,Ivan Borbath,Dieter Häussinger,Tom Giannaris,Minghua Shan,M. Moscovici,D. Voliotis,Jordi Bruix +23 more
TL;DR: In patients with advanced hepatocellular carcinoma, median survival and the time to radiologic progression were nearly 3 months longer for patients treated with sorafenib than for those given placebo.
Journal ArticleDOI
Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis
Vincenzo Mazzaferro,Josep M. Llovet,Rosalba Miceli,Sherrie Bhoori,M. Schiavo,Luigi Mariani,Tiziana Camerini,Sasan Roayaie,Myron Schwartz,Gian Luca Grazi,René Adam,Peter Neuhaus,Mauro Salizzoni,Jordi Bruix,Alejandro Forner,Luciano De Carlis,Umberto Cillo,Andrew K. Burroughs,Roberto Troisi,Massimo Rossi,Giorgio Enrico Gerunda,Jan Lerut,Jacques Belghiti,Ilka de Fátima Santana Ferreira Boin,Jean Gugenheim,Fedja Rochling,Bart van Hoek,Pietro Majno +27 more
TL;DR: More patients with hepatocellular carcinoma could be candidates for transplantation if the current dual approach to candidacy, based on the strict Milan criteria, were replaced with a more precise estimation of survival contouring individual tumour characteristics and use of the up-to-seven criteria.
Journal ArticleDOI
Current strategy for staging and treatment: the BCLC update and future prospects.
TL;DR: Early-stage HCC patients should be considered for potentially curative options such as resection, ablation, and transplantation, while patients at intermediate stage benefit from chemoembolization, whereas patients at an advanced stage, or who cannot benefit from options of higher priority, have sorafenib as the standard treatment.
Journal ArticleDOI
Cholangiocarcinoma 2020: the next horizon in mechanisms and management
Jesus M. Banales,Jesus M. Banales,Jesus M. Banales,Jose J.G. Marin,Jose J.G. Marin,Angela Lamarca,Angela Lamarca,Pedro M. Rodrigues,Shahid A. Khan,Lewis R. Roberts,Vincenzo Cardinale,Guido Carpino,Jesper B. Andersen,Chiara Braconi,Diego F. Calvisi,Maria J. Perugorria,Maria J. Perugorria,Luca Fabris,Luca Fabris,Luke Boulter,Rocio I.R. Macias,Rocio I.R. Macias,Eugenio Gaudio,Domenico Alvaro,Sergio A. Gradilone,Mario Strazzabosco,Mario Strazzabosco,Marco Marzioni,Cédric Coulouarn,Laura Fouassier,Chiara Raggi,Pietro Invernizzi,Joachim C. Mertens,Anja Moncsek,Sumera Rizvi,Julie K. Heimbach,Bas Groot Koerkamp,Jordi Bruix,Jordi Bruix,Alejandro Forner,Alejandro Forner,John Bridgewater,Juan W. Valle,Juan W. Valle,Gregory J. Gores +44 more
TL;DR: This expert Consensus Statement, endorsed by the ENS-CCA, summarizes the latest advances in CCA, including classification, genetics and treatment, and provides recommendations for CCA management and priorities across basic, translational and clinical research.
Journal ArticleDOI
Chemoembolization of hepatocellular carcinoma with drug eluting beads: efficacy and doxorubicin pharmacokinetics.
Maria Varela,Maria Isabel Real,Marta Burrel,Alejandro Forner,Margarita Sala,Mercè Brunet,Carmen Ayuso,Lluis Castells,Xavier Montaña,Josep M. Llovet,Jordi Bruix +10 more
TL;DR: Chemoembolization using DEBs is an effective procedure with a favorable pharmacokinetic profile and after a median follow-up of 27.6 months, 1- and 2-year survival is 92.5% and 88.9%, respectively.